The Impact of Sinopharm COVID-19 Vaccination on Male Fertility

NCT ID: NCT04946565

Last Updated: 2021-07-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-07-03

Study Completion Date

2022-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators shall study the effect of Sinopharm vaccination on semen parameters and serum testosterone

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators shall compare semen parameter (sperm density, sperm motility, and percentage of abnormal sperm form) as well as morning serum testosterone before vaccination, and 3 months after the second dose of the vaccine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Male Infertility Hypogonadism, Male

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sinopharm vaccine group

Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.

Semen analysis

Intervention Type DIAGNOSTIC_TEST

Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Semen analysis

Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Receiving Sinopharm COVID-19 vaccines Male age 18-50 years old

Exclusion Criteria

* Adults unable to consent
* Men who have been receiving Testosterone replacement therapy or anabolic steroids within the last year
* Men with a history of male infertility
* Men with a genetic or other medical condition known to be associated with decreased semen parameters Positive COVID-19 PCR test within the 3 months
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cairo University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed Tarek Anis

Professor of Andrology

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mohamed Tarek H Anis, M.D.

Role: PRINCIPAL_INVESTIGATOR

Cairo University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Faculty of Medicine, Cairo University

Cairo, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mohamed Tarek H Anis, M.D.

Role: CONTACT

+201222163858

Islam Fathy, M.D.

Role: CONTACT

+201004244360

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TBA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Contraception in Normal and Subnormal Men
NCT00167141 TERMINATED PHASE2